Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth
Stibilj joins after a year of expansion that included Hongyi Clinical Development Services, giving Emerald Clinical a platform with 1,000+ professionals across 40+ countries.
- On Thursday, October 1, 2026, Emerald Clinical Trials announced the appointment of Michael Stibilj as Chief Executive Officer to lead the company's next phase of global growth.
- Stibilj brings over 30 years of global CRO industry experience, having previously served as Chief Operating Officer at Novotech and CEO at PPC Group and IQVIA.
- Following a transformative year that included the acquisition of Hongyi Clinical Development Services, Emerald now operates with 1,000 professionals across 40 countries and 70 locations.
- Interim CEO Glenn Kerkhof remains on the Board to advise the company, while Chairman of the Board Sean Carney thanked him for his leadership during the transition.
- Stibilj emphasized that technological advances at the intersection of global reach and Asia-Pacific depth will shape clinical research, with commitment to high-quality delivery and transparency.
40 Articles
40 Articles
Emerald Clinical Trials Appoints Michael Stibilj as CEO
LoudounTimes.com
Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth
SINGAPORE, Sept. 30, 2026 /PRNewswire/ -- Emerald Clinical Trials, a leading global clinical research organization anchored in Asia-Pacific, today announced the appointment of Michael Stibilj as Chief Executive Officer, effective 1 October 2026. The appointment marks the beginning of the…
Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth - Business News Week
SINGAPORE, Oct. 1, 2026 /PRNewswire/ — Emerald Clinical Trials, a leading global clinical research organization anchored in Asia-Pacific, today announced the appointment of Michael Stibilj as Chief Executive Officer, effective 1 October 2026. The appointment marks the beginning of the company’s next phase of growth. Michael brings over 30 years of global CRO industry experience. He joins […] The post Emerald Clinical Trials Appoints Michael Stib…
Coverage Details
Bias Distribution
- 66% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
